In 2017, the FDA more than doubled the number of drugs it approved compared with the previous year, with 46 novel medicines receiving the FDA’s endorsement in 2017.
In 2017, the FDA more than doubled the number of drugs it approved compared with the previous year, with 46 novel medicines receiving the FDA’s endorsement in 2017, according to Reuters.
The European Union also saw an increase in drug approvals, with 92 drugs receiving the green light in 2017, including generics, which were up from 81 in 2016.
Despite the increase in approvals, some of the world’s largest drug makers saw average returns in 2017, which reflects the competition of the industry as well as the growing share of new products being produced by younger biotech companies.
Consultancy company Deloitte said that the projected research and development returns at 12 of the world’s top drug makers were at an 8-year low at only 3.2% (down from 10.1% in 2010).
It is important to note, however, that the US drug approval tally for 2017 does not include the first of a new wave of cell and gene therapies from drug companies Novartis, Gilead Sciences, and Spark therapeutics, all approved in 2017 under a separate category.
Biosimilars also made an impact in the FDA’s bottom line for approved drugs in 2017:
For 2018, drug makers have more new products waiting in the wings; however, the pace of FDA approvals may lag due to the fact that several drugs that were expected to be cleared in the first quarter of 2018 were actually approved in 2017.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.